GC5107

immune globulin intravenous (human) · Green Cross Corporation

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for GC5107, covering 2022-10-28 to 2022-10-28. Get the full timeline:

Most recent: Clinical Trial Update: Study of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency [Phase 3]